BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8339387)

  • 1. Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.
    Stewart DJ; Grewaal D; Redmond MD; Mikhael NZ; Montpetit VA; Goel R; Green RM
    Cancer Chemother Pharmacol; 1993; 32(5):368-72. PubMed ID: 8339387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human autopsy-tissue distribution of menogaril and its metabolites.
    Stewart DJ; Grewaal D; Green RM; Goel R; Mikhael N; Montpetit VA; Redmond D; Earhart R
    Cancer Chemother Pharmacol; 1993; 32(5):373-8. PubMed ID: 8339388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives.
    Clark PI
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):20-7. PubMed ID: 1411635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.
    Holthuis JJ
    Pharm Weekbl Sci; 1988 Jun; 10(3):101-16. PubMed ID: 3047665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
    Montaldo PG; Figoli F; Zanette ML; Sorio R; Zucchetti M; Tirelli U; D'Incalci M
    Oncology; 1990; 47(1):55-61. PubMed ID: 2300386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedule-dependent topoisomerase II-inhibiting drugs.
    Joel SP; Slevin ML
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S84-8. PubMed ID: 8070033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection.
    Sinkule JA; Evans WE
    J Pharm Sci; 1984 Feb; 73(2):164-8. PubMed ID: 6707876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of VP16 and VM26 in human brain tumors.
    Zucchetti M; Rossi C; Knerich R; Donelli MG; Butti G; Silvani V; Gaetani P; D'Incalci M
    Ann Oncol; 1991 Jan; 2(1):63-6. PubMed ID: 2009235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4.
    Relling MV; Nemec J; Schuetz EG; Schuetz JD; Gonzalez FJ; Korzekwa KR
    Mol Pharmacol; 1994 Feb; 45(2):352-8. PubMed ID: 8114683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teniposide in the treatment of small cell lung cancer: a review.
    Hansen HH; Dombernowsky P; Hansen M; Bork E
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):65-8. PubMed ID: 1329227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.
    Pui CH; Ribeiro RC; Hancock ML; Rivera GK; Evans WE; Raimondi SC; Head DR; Behm FG; Mahmoud MH; Sandlund JT
    N Engl J Med; 1991 Dec; 325(24):1682-7. PubMed ID: 1944468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute bioavailability and pharmacokinetics of oral teniposide.
    Splinter TA; Holthuis JJ; Kok TC; Post MH
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):28-34. PubMed ID: 1411636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins.
    McLeod HL; Evans WE
    Cancer Surv; 1993; 17():253-68. PubMed ID: 8137343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of epipodophyllotoxin derivatives in bladder cancer.
    Serretta V; Ingargiola GB; Pavone-Macaluso M
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):81-4. PubMed ID: 1411641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?
    Allen LM; Tejada F; Okonmah AD; Nordqvist S
    Cancer Chemother Pharmacol; 1982; 7(2-3):151-6. PubMed ID: 7083456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human autopsy tissue concentrations of mitoxantrone.
    Stewart DJ; Green RM; Mikhael NZ; Montpetit V; Thibault M; Maroun JA
    Cancer Treat Rep; 1986 Nov; 70(11):1255-61. PubMed ID: 3768871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
    Ehninger G; Proksch B; Wanner T; Schuler U; Busch FW; Schmidt H; Schleyer E; Jaschonek K; Hiddemann W
    Leukemia; 1992 Jun; 6(6):582-7. PubMed ID: 1602795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues.
    Stewart DJ; Grewaal D; Green RM; Mikhael N; Goel R; Montpetit VA; Redmond MD
    Anticancer Res; 1993; 13(6A):1945-52. PubMed ID: 8297100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical pharmacology of etoposide and teniposide.
    Clark PI; Slevin ML
    Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.